Your browser doesn't support javascript.
loading
The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients.
Friedrich, Mirco J; Neri, Paola; Kehl, Niklas; Michel, Julius; Steiger, Simon; Kilian, Michael; Leblay, Noémie; Maity, Ranjan; Sankowski, Roman; Lee, Holly; Barakat, Elie; Ahn, Sungwoo; Weinhold, Niels; Rippe, Karsten; Bunse, Lukas; Platten, Michael; Goldschmidt, Hartmut; Müller-Tidow, Carsten; Raab, Marc-Steffen; Bahlis, Nizar J.
Affiliation
  • Friedrich MJ; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: mfriedri@broadinstitute.org.
  • Neri P; Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada; Tom Baker Cancer Center, Department of Hematology and Oncology, Calgary, Canada.
  • Kehl N; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Michel J; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Steiger S; Division of Chromatin Networks, BioQuant Center & German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
  • Kilian M; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Leblay N; Tom Baker Cancer Center, Department of Hematology and Oncology, Calgary, Canada.
  • Maity R; Tom Baker Cancer Center, Department of Hematology and Oncology, Calgary, Canada.
  • Sankowski R; Department of Neuropathology, Freiburg University Hospital, Freiburg, Germany.
  • Lee H; Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada; Tom Baker Cancer Center, Department of Hematology and Oncology, Calgary, Canada.
  • Barakat E; Tom Baker Cancer Center, Department of Hematology and Oncology, Calgary, Canada.
  • Ahn S; Tom Baker Cancer Center, Department of Hematology and Oncology, Calgary, Canada.
  • Weinhold N; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
  • Rippe K; Division of Chromatin Networks, BioQuant Center & German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Bunse L; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Platten M; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Helmholtz Institute of Translational Oncology (HI-TRON), Mainz, Germany;
  • Goldschmidt H; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Müller-Tidow C; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Raab MS; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: marc.raab@med.uni-heidelberg.de.
  • Bahlis NJ; Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada; Tom Baker Cancer Center, Department of Hematology and Oncology, Calgary, Canada. Electronic address: nbahlis@ucalgary.ca.
Cancer Cell ; 41(4): 711-725.e6, 2023 04 10.
Article in En | MEDLINE | ID: mdl-36898378
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Bispecific / Multiple Myeloma Type of study: Prognostic_studies Limits: Humans Language: En Journal: Cancer Cell Journal subject: NEOPLASIAS Year: 2023 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Bispecific / Multiple Myeloma Type of study: Prognostic_studies Limits: Humans Language: En Journal: Cancer Cell Journal subject: NEOPLASIAS Year: 2023 Document type: Article